29 results about "Atropine" patented technology

Provided is a method for producing a solution of atropine with improved recovery. A method for producing a solution of atropine-211, comprising the steps of: irradiating bismuth with alpha rays, generating atropine-211 in the bismuth, and distilling the bismuth irradiated with the alpha rays, separating and purifying atropine-211, and dissolving it in an aqueous sodium bicarbonate solution.

The invention pertains to a new formulation of atropine in the form of a gel, in particular for use for the treatment of treatment of sialorrhea.

The invention discloses an atropine derivative and a preparation method and application thereof, and belongs to the technical field of medical preparations, the atropine derivative and a salt or a pharmaceutical composition thereof can be used as a ciliary muscle paralysis agent and / or a mydriasis agent; the choroid and sclera functions can be regulated and controlled by improving choroid microcirculation and sclera hypoxia environment, inhibiting an HIF-1alpha signal channel and directly targeting sclera fibroblasts to inhibit extracellular matrix generation and remodeling; the medicine is used for relieving muscae volitantes symptoms; amblyopia, lazy eye diseases or myopia can be relieved; for treating or preventing myopia; the traditional Chinese medicine composition has good maintenance time and treatment effect, can obviously reduce the use frequency and use amount, improves the use experience, and reduces the medicine use cost.

The invention relates to an application of atropine (Atropine, C17H23NO3) in preparation of a medicine for treating sleep disorder. Existing sleep drugs are generally ineffective to sleep disorders related to circadian rhythm and cannot restore a normal sleep-awakening period for many patients, and benzodiazepine and non-benzodiazepine hypnotics have significant side effects such as dependency, cognitive disorder and dizziness, and long-term use of the drugs is limited. According to the invention, a per3 gene defect zebrafish model is used for drug screening, and a new application of a clinically used drug, namely atropine, in preparation of drugs for treating sleep disorders is provided for the first time, especially for treating sleep disorders which are insensitive to existing sedative drugs or are related to circadian rhythm disorder, and particularly for treating sleep disorders which are not sensitive to existing sedative drugs or are related to circadian rhythm disorder, circadian rhythm disorder, circadian rhythm disorder and circadian rhythm disorder. The optimal curative effect can be achieved in the indication by 12 mu M, the sleep-awakening cycle disorder caused by Per3 defects is improved, and the normal sleep-awakening cycle is recovered.

The invention belongs to the technical field of medicine. The invention relates to the field of eye drops, in particular to application of ipratropium bromide in the aspect of preventing or improving myopia and eye drops containing ipratropium bromide. The research proves that the single drug of the ipratropium bromide can effectively inhibit the growth of the ocular axis and the deterioration of the diopter, and the brand new medicinal value of the ipratropium bromide in the aspect of preventing and improving the myopia is disclosed for the first time. More importantly, the invention finds that the combination of the ipratropium bromide and the diquafosol sodium can generate a remarkable synergistic effect, and the curative effect of the combined preparation is far better than that of a single drug and even better than that of a clinical drug atropine. The invention provides a safe, effective and long-term brand new drug choice for myopia prevention and control, and has good application prospect and value.

An eye drop composition for the prevention or treatment of ophthalmic diseases is provided, including: (a) a lyophilized preparation including atropine or a pharmaceutically acceptable salt thereof; and (b) a reconstituting diluent, the lyophilized preparation being separate from the reconstituting diluent. A method for preparing the eye drop composition is also provided, which includes steps of: (a) contacting a buffer salt system in the lyophilized preparation with the atropine or the pharmaceutically acceptable salt thereof, and optionally, one or more of a matrix agent and a stabilizer, and lyophilizing to obtain the lyophilized preparation; and (b) contacting a buffer salt system in the reconstitution diluent optionally with one or more of an osmotic pressure regulator, a chelating agent, and a bacteriostatic agent to obtain the reconstitution diluent.

The utility model discloses an out-of-focus and dot matrix composite lens for early-stage myopia prevention, which comprises a lens main body, a correction area, a central optical correction area, an out-of-focus prevention and control area and a dot matrix area, and the central optical correction area adopts a positive spherical lens. Compared with the prior art, the pair of glasses has the advantages that 1, a small number of positive spherical lenses are additionally arranged in the central optical area of the main lens, teenagers with insufficient hyperopia reserve are compensated, and the development speed of an eye axis is intervened, so that the effect of delaying the occurrence and development of myopia in the early stage of myopia is realized; 2, the safety is better than that of medicine relaxation, no side effect exists, mydriasis medicine atropine is replaced by optical relaxation, no side effect exists, the safety is higher, hyperopia out-of-focus and focusing pressure can be reduced when the eyes see far and near, and the eyes are easier to use; and 3, a dot matrix area is added in the out-of-focus gap, so that the contrast sensitivity can be further reduced, the stimulation of a high-contrast visual signal to retina cone cells is reduced, and the effect of preventing myopia is improved.

The invention discloses an atropine myopia prevention and control evidence-based dialogue method and system, and belongs to the technical field of prevention and control data intelligence. The method comprises the steps of question analysis: performing semantic analysis on a received user question; retrieval of evidence-based evidences: performing retrieval enhancement according to a semantic analysis result, and obtaining the evidence-based evidences and sources and levels of the evidence-based evidences from the atropine myopia prevention and control knowledge graph; inference chain generation: combining evidence-based evidences with cues, and guiding the model to generate inference chain content according to the steps of individual core feature analysis, atropine prevention and control scheme matching, safety evaluation and scheme optimization through a thinking chain CoT; and answer generation: according to the evidence-based evidence and the reasoning chain content, generating different types of atropine myopia prevention and control answers. According to the method and the device, the matching between each core entity in the output atropine myopia prevention and control scheme and individual requirements is improved, and the accuracy of the atropine myopia prevention and control scheme is improved.

The invention discloses a 5-fluorouracil atropine double-drug sustained release preparation based on temperature-sensitive hydrogel as well as a preparation method and application of the 5-fluorouracil atropine double-drug sustained release preparation. The double-drug sustained release preparation is prepared from the following raw materials: a vagus nerve blocking agent, 5-fluorouracil (5-FU) and temperature-sensitive hydrogel (PLEL), wherein the vagus nerve blocking agent comprises atropine. According to the invention, the chemotherapeutic drug 5-FU and the vagus nerve signal blocking agent (such as atropine) are co-delivered through the temperature-sensitive hydrogel for the first time to realize'double strike 'on gastric cancer tumors, that is, tumor cells are directly killed and cancer-promoting nerve signals are blocked, so that the treatment effect on gastric cancer is remarkably improved. Besides, the double-drug sustained-release preparation is high in safety and good in sustained-release effect, 5-FU and the vagus nerve blocker can be accurately delivered to a tumor area through local injection and in-situ gelation of the temperature-sensitive hydrogel, whole-body exposure of the drug is reduced, local residence time is prolonged, and toxic and side effects are reduced.

The present invention belongs to the field of pharmaceutical preparations and specifically relates to an atropine pharmaceutical composition comprising a pharmaceutically acceptable salt of atropine, a sulfonic acid cation exchange resin, and a suspending agent, wherein the suspending agent is selected from one or more of carbomer, povidone, and hydroxyethylcellulose. The atropine pharmaceutical composition of the present invention can significantly reduce the free atropine content in the drug solution, thereby controlling the content of related substances within a low range, ensuring the drug has excellent stability at room temperature and achieving a better drug release effect.

A liquid ophthalmic composition comprising atropine or a pharmaceutically acceptable salt thereof, at least one buffering agent and at least one tonic agent, wherein Atropine or a pharmaceutically acceptable salt thereof is present in the composition in an amount of 0.001% to 0.1% by weight. that at least one buffering agent is present in the composition at a concentration of 0.5 mM to 50 mM, that at least one tonic agent is present in the composition at a concentration of 100 mM to 500 mM, the composition has a pH value of 4.0 to 6.0.

The present invention provides an aqueous pharmaceutical composition for the treatment of myopia, prevention of myopia and / or suppression of myopia, comprising atropine or a salt thereof in a concentration of 0.025% (w / v), wherein the aqueous pharmaceutical composition is administered to a myopic patient aged 12 to 15 years.

Gel, ointment, lotion, or cream formulations containing an active pharmaceutical ingredient including a tropanil portion are provided herein. The gel, lotion, or cream formulations may contain at least one low molecular weight (LMW) compound or a pharmaceutically acceptable salt thereof. Also provided herein are gel, ointment, lotion, or cream formulations containing active pharmaceutical ingredients such as atropine, pilocarpine, physostigmine, or travoprost.

The present disclosure is directed, in part, to aqueous pharmaceutical solutions comprising benzyl atropine or a pharmaceutically acceptable salt or prodrug thereof, at least one buffer, at least one tonicity agent, and at least one solubilizing agent, processes of preparing an aqueous solution comprising benzyl atropine, the products of such processes, and methods of preventing myopia, treating myopia, reducing myopia progression, or preventing myopia progression in a subject in need thereof, by administering to the eye of the subject a therapeutically effective amount of such an aqueous pharmaceutical solution.

Ophthalmically-acceptable formulations of atropine and other muscarinic acetylcholine receptor antagonists are provided that can be heat-sterilized without significant degradation of the muscarinic acetylcholine receptor antagonist. The formulations are less acidic than prior muscarinic acetylcholine receptor antagonist ophthalmic formulations, making them more comfortable when administered to the eye.

The application belongs to the field of medicine, and provides atropine salt, a preparation method thereof, a pharmaceutical composition and application. The atropine salt derivative prepared in the application has high activity in the preparation of eye drugs, and has high stability. The compound has good mydriatic effect. The atropine salt derivative prepared in the application has high solubility and stability, and has significant advantages in the preparation of eye drugs and application.

Provided herein are gels, ointments, lotions, or cream formulations comprising an active pharmaceutical ingredient comprising a tropane moiety. The gel, lotion, or cream formulation may comprise at least one low molecular weight (LMW) compound, or a pharmaceutically acceptable salt thereof. Also provided herein are gel, ointment, lotion, or cream formulations comprising an active agent, such as atropine, pilocarpine, hyacinth bean alkali, or travoprost.

The present application provides compositions, methods, and dispensers for topical delivery of ophthalmological active pharmaceutical ingredients (APIs).In one example, a composition is provided comprising an active pharmaceutical ingredient soluble in MCT wherein the API is not atropine or a salt thereof, a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound. In another example, a nano-emulsion is provided comprising about an active pharmaceutical ingredient soluble in MCT; a medium chain triglyceride (MCT); and a semi-fluorinated alkane compound, wherein the nano-emulsion has a droplet particle size D90 of less than about 100 nm. Dispensers containing the compositions are also provided and include glass and polyethylene terephthalate dispensers or containers. Methods of using the compositions are also provided and include a method for treating an ocular condition in a subject comprising administering the compositions or nano-emulsions to an eye of the subject.The present application also provides compositions and methods for treating ophthalmological conditions such as presbyopia and glaucoma. The compositions can comprise a muscarinic cholinergic receptor agonist and a semi-fluorinated alkane compound; or can comprise a muscarinic cholinergic receptor agonist, a semi-fluorinated alkane compound, and an organic cosolvent. The compositions can confer chemical stability of the muscarinic cholinergic receptor agonist.

To provide a medicine that exhibits effects such as improving myopia and suppressing the progression of myopia in young patients. [Solution] An aqueous pharmaceutical composition for the treatment, prevention and / or inhibition of myopia, comprising a 0.025% (w / v) concentration of atropine or a salt thereof, characterized in that it is used to be administered to myopic patients aged 12 to 15 years.

Disclosed herein is an aqueous composition comprising 0.001-0.1% (w / v) atropine or a salt thereof, a water-soluble polymer, and buffer (I), which is at a pH range of 6 or lower, wherein the buffer (I) is at least one selected from the group consisting of a phosphate buffer, an aminocarboxylate buffer, a carbonate buffer, an acetate buffer, a tartrate buffer, a borate buffer, and trometamol.

The invention belongs to the technical field of biological medicines, and relates to atropine-carrying responsive disintegrating nanoparticles, a preparation method and application of the atropine-carrying responsive disintegrating nanoparticles in myopia treatment. In particular to an atropine-loaded responsiveness disintegrating nanoparticle, a preparation method of the nanoparticle and a method for treating myopia through precise space-time regulation and control on a sclera fibroblast microenvironment. The invention firstly provides a targeted ROS responsive disintegration nanoparticle, the nanoparticle takes Zn < 2 + > as a center and reacts with a ligand H2L to form a spherical nanoparticle through self-assembly, and L represents C11H18O4S < 2->.

Myopia progression is safely and effectively reduced by topical administration of a storage-stable low-dose formulation in which atropine is present at a concentration of 0.01%. Unexpectedly, such formulation was proven more effective to reduce myopia progression as compared to an otherwise identical formulation containing 0.02% atropine. For example, formulations with an atropine concentration of about 0.01% slowed down myopia progression as compared to subjects not receiving treatment.

The present invention belongs to the field of pharmaceutical formulations, and specifically relates to an atropine pharmaceutical composition, comprising an atropine pharmaceutically acceptable salt, a sulfonic acid-based cation exchange resin, and a suspending agent. The suspending agent is selected from one or more of carbomer, povidone, and hydroxyethyl cellulose. The formulation of the atropine pharmaceutical composition of the present invention can significantly reduce the content of free atropine in a medicinal solution and thus can control the content of related substances within a relatively low range, so that the drug has superior stability at room temperature and a superior drug release effect.

The present invention provides aqueous pharmaceutical compositions for the treatment, prevention, and / or inhibition of the progression of myopia. [Solution] An aqueous pharmaceutical composition containing atropine or a salt thereof at a concentration of 0.025% (w / v), characterized in that it is used for administration to myopic patients aged 12 to 15 years.

The invention relates to a compound atropine composition as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides a compound atropine composition, which comprises a side effect antagonist and 0.02-0.1 wt% of atropine, the mass ratio of atropine to side effect antagonist is atropine: side effect antagonist = 1: (0.01-500), and atropine comprises at least one of an atropine monomer, a pharmaceutically acceptable salt of atropine and an atropine derivative. The side effect antagonist and the atropine are matched to form the compound atropine composition, so that the side effects (such as photophobia, pupil distension and the like) caused by the atropine in the myopia control process can be effectively improved, and meanwhile, the atropine in the composition has the activity of inhibiting ocular axis growth so as to delay the myopia progress; the compliance of a user can be effectively improved, and the continuity and the final effect of myopia control treatment are ensured.

To provide an ophthalmic composition of atropine that can be stored for a long period of time. [Solution] An ophthalmic composition having a pH of about 4.2 to about 6.4 and comprising about 0.001 wt% to about 0.05 wt% of atropine or a pharmaceutically acceptable salt thereof, glycerin, and water, wherein after two weeks under storage conditions at 40°C and 75% relative humidity, the ophthalmic composition contains, based on the initial concentration, at least about 80%, at least about 85%, at least about 90%, at least about 93%, at least about 95%, at least about 97%, at least about 98%, or at least about 99% of the atropine or a pharmaceutically acceptable salt thereof.

The present invention relates to a membrane-changing multi-point defocus eyeglass lens and a preparation method thereof, comprising a rear surface protective film layer, a multi-point defocus substrate, a composite color-changing film layer, and a front surface protective film layer, which are sequentially arranged from the human eye side to the light incident side; the multi-point defocus substrate is sequentially arranged from the center to the edge as a central viewing area, a multi-point defocus area, and an edge viewing area; the front surface of the multi-point defocus area is provided with N circles of non-continuous, dot-shaped microlenses; the composite color-changing film layer is a sequentially spin-coated N+1-layer single-layer color-changing film, the first N layers of single-layer color-changing film sequentially covering each circle of microlenses, and the N+1th layer of single-layer color-changing film covering the entire front surface of the multi-point defocus substrate. The present invention adopts a membrane-changing color-changing composite multi-point defocusing function, which can not only intervene and adjust the problem of worsening myopia caused by compensatory elongation of the eye axis, but also prevent strong light from damaging the human eye, thereby achieving multiple protections for the human eye. It can be used in conjunction with atropine eye drops and can effectively alleviate adverse reactions such as photophobia caused by atropine eye drops.

The present invention provides ophthalmic acceptable formulations of atropine and other muscarinic acetylcholine receptor antagonists, which can be heat sterilized without significant degradation of the muscarinic acetylcholine receptor antagonists. The formulations are less acidic than previous muscarinic acetylcholine receptor antagonist ocular formulations, making them more comfortable when administered to the eye.

The invention discloses a photoetching ultrastructure multifunctional lens for preventing and delaying myopia, which comprises a lens main body, and a functional area is arranged in the lens main body. Compared with the prior art, the ultra-micro lens has the advantages that the ultra-micro lens forms a dense negative out-of-focus signal interference area, when eyes rotate, light passing through the area can generate irregular dynamic changes in different states of convergence, divergence and the like, meanwhile, the light is diffused at gap composite points of the photoetching ultra-micro lens, and the light intensity is improved. By means of the comprehensive design, the intensity of the negative defocus signals reaching the retina can be weakened to the maximum extent, the brain is prevented from receiving the negative defocus signals possibly accelerating myopia development, and then the effect that myopia occurrence and development are delayed in a nearly non-inductive mode is achieved. For the photophobia phenomenon occurring when low-concentration atropine is used for preventing and controlling myopia, a color-changing film layer can be additionally arranged to adjust the brightness of light rays entering eyes so as to relieve symptoms.